MediciNova rises as drug shows promise in COVID trial

Medicinova

08/06/2022 13:06

** Shares of biopharmaceutical company  MNOV.O  rise 11.9%
to $2.63 premarket
    ** Co reports positive results from a mid-stage trial of its
experimental therapy, MN-166, in hospitalized COVID-19 patients
at risk for developing acute respiratory distress syndrome (https://refini.tv/3xf8iKb)
    ** Plans to discuss results with the FDA to determine next
steps
    ** MN-166 is also being tested for amyotrophic lateral
sclerosis, progressive multiple sclerosis and other neurological
conditions
    ** Up to Tuesday's close, stock down ~12.3% this year
    

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))